Finding studies
Finding studies
Take this into the appointment.
Saves the questions and what to expect into your notes, next to the visit they belong to.
Lead
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
The study is a randomized, double-blind phase 1 trial including 2 sequential parts: single ascending dose(SAD) part,multiple ascending dose(MAD) part. SAD and MAD are dose-escalated tolerant study designing. The aims of the study as below: 1. Evaluating the safety and tolerance of ZG0418 in ALK+ NSCLC. 2. Evaluating the fasting pharmacokinetic parameters of ZG0418 in ALK+ NSCLCJaktinib. 3. Evaluating the postprandial pharmacokinetic parameters of ZG0418 in ALK+ NSCLC. 4. Analysis the metabolites of ZG0418
Age
18–75
Sex
ALL
Healthy volunteers
Not accepted
